Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis


23 Nov 2019


Poster display session


Tumour Site

Colon and Rectal Cancer


Michio Nakamura


Annals of Oncology (2019) 30 (suppl_9): ix30-ix41. 10.1093/annonc/mdz421


M. Nakamura1, S. Yuki2, N. Takahashi3, T. Shichinohe4, H. Nakatsumi5, Y. Kawamoto2, T. Kusumi6, A. Ishiguro7, K. Harada8, I. Iwanaga9, K. Hatanaka10, K. Oomori11, N. Senmaru12, K. Iwai13, M. Koike14, N. Sakamoto2, A. Taketomi15, S. Hirano4, N. Nishimoto16, Y. Komatsu5

Author affiliations

  • 1 Gastroenterology, Sapporo City General Hospital, 060-8604 - Sapporo/JP
  • 2 Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 3 Surgical Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 4 Gastroenterological Surgery Ii, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 5 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 6 Surgery, Keiyukai Sapporo Hospital, 003-0027 - Sapporo/JP
  • 7 Medical Oncology, Teine Keijinkai Hospital, 006-8555 - Sapporo/JP
  • 8 Medical Oncology, Kushiro Rosai Hospital, 085-8533 - Kushiro/JP
  • 9 Medical Oncology, Japanese Red Cross Kitami Hospital, 090-8666 - Kitami/JP
  • 10 Gastroenterology, Hakodate Municipal Hospital, 041-8680 - Hakodate/JP
  • 11 Surgery, Keiwakai Ebetsu Hospital, 069-0817 - Ebetsu/JP
  • 12 Surgery, Steel Memorial Muroran Hospital, 050-0076 - Muroran/JP
  • 13 Surgery, Oji General Hospital, 053-8506 - Tomakomai/JP
  • 14 Surgery, KKR Sapporo Medical Center, 062-0931 - Sapporo/JP
  • 15 Gastroenterological Surgery I, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 16 Clinical Research And Medical Innovation Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 94P


FOLFOX and CAPOX are standard adjuvant chemotherapy for resected stage III colon cancer. MOSAIC and XELOXA trials were performed outside of Japan, thus, we conducted a phase II study (NORTH/HGCSG1003) to assess the efficacy and safety of FOLFOX as adjuvant chemotherapy for Japanese patients(pts) with resected stage III colon cancer (UMIN ID: 000004590).


This phase II study enrolled patients with resected stage III colon cancer. Patients received 12 cycles of FOLFOX4 or mFOLFOX6. Sample size was determined to be 243 pts. Primary endpoint was disease-free survival (DFS). We assumed an expected 3-year DFS rate of 81.2% in this study. Secondary endpoints included overall survival (OS) and safety. In this meeting, we present for the 5-year OS rate.


From Sep 2010 to Mar 2013, 273 pts were enrolled at 28 institutions. Full analysis included 265 patients who received FOLFOX. Patients characteristics were as follows: median age; 65(33-84), Male/female; 131/134, PS 0/1; 258/7, stage IIIA/IIIB/IIIC; 37/197/31, colon/rectosigmoid: 214/51. The most common grade 3-4 adverse events were neutrophil count decreased (48.1%), peripheral sensory neuropathy (6.4%), platelet count decreased (2.3%), and allergic reaction (1.5%). The median number of cycles of FOLFOX was 12, and the completion treatment rate was 80.4%. There was no treatment-related death. The 3-year/5-year DFS rate was 76.0%(95%C.I. 70.3- 80.7)/70.6%(95%C.I. 64.7-75.7). The 3-year/5-year 0S rate was 95.8%(95%C.I. 92.5- 97.7)/88.1%(95%C.I. 83.5-91.5).


In Japanese patients with resected stage III colon cancer, FOLFOX is a well-tolerable regimen as adjuvant chemotherapy. In this trial, the 3-year DFS rate of primary endpoint was not meet the expectation. However, the 3-year DFS and 5-year OS rate in this trial were similar to several pivotal trials.

Clinical trial identification

UMIN ID: 000004590.

Editorial acknowledgement

Legal entity responsible for the study

Non-Political Organization: Hokkaido Gastrointestinal Cancer Study Group.


Non-Political Organization: Hokkaido Gastrointestinal Cancer Study Group.


S. Yuki: Honoraria (self): Yakult Honsha Co. Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.